Online inquiry

IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1869MR)

This product GTTS-WQ1869MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CTLA4 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001037631.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1493
UniProt ID P16410
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ1869MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10807MR IVTScrip™ mRNA-Anti-G, M777-16-3(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA M777-16-3
GTTS-WQ4978MR IVTScrip™ mRNA-Anti-GP, c2G4-N(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA c2G4-N
GTTS-WQ6476MR IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CT-P-59
GTTS-WQ8114MR IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HGS-ETR2
GTTS-WQ10704MR IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA M-1095
GTTS-WQ12294MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MSB-0010718C
GTTS-WQ7023MR IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Fab C225
GTTS-WQ3646MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1187982(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BAY 1187982
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW